Remestemcel-L

Phase 3Cell therapy

MMesoblast, Ltd.

Remestemcel-L is one of 98 small molecule programs targeting Colitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ColitisActive, not recruiting

Ulcerative ColitisActive, not recruiting

COVID-19Active, not recruiting

Acute Respiratory Distress SyndromeActive, not recruiting

ColitisPhase 1/Phase 2

Active, not recruiting

Ulcerative ColitisPhase 1/Phase 2

Active, not recruiting

COVID-19Phase 3

Active, not recruiting

Acute Respiratory Distress SyndromePreclinical

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Remestemcel-L

MMesoblast, Ltd.

Phase 3

2 2

Piperacillin/tazobactam

Pfizer

Preclinical

1 3

Achromycin V

WWyeth-Lederle Vaccines

Aprotinin

1 5

Blood Taken

HHospices Civils de Lyon

Preclinical

1 6

Antithrombin-III

Octapharma

Preclinical

1 7

Conventional

PPopulation Health Research Institute

Preclinical

1 8

DAS181

AAnsun Biopharma, Inc.

Preclinical

4 9

Exoflo

DDirect Biologics, LLC

Preclinical

3 10

Moderna COVID-19 Vaccine

Moderna

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

COVID-192 trials

MSCs in COVID-19 ARDS

Terminated·IIcahn School of Medicine at Mount Sinai·Phase 3·NCT04371393·223 enrolled

Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)

No longer available·MMesoblast International Sàrl··NCT04456439

Ulcerative Colitis1 trial

Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Ulcerative Colitis (UC)

Unknown status·TThe Cleveland Clinic·Phase 1/2·NCT04543994·24 enrolled

Treatment1 trial

Safety Follow-up of Treatment With Remestemcel-L in Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute GVHD

Completed·MMesoblast, Ltd.·Phase 3·NCT02652130·32 enrolled

Acute Respiratory Distress Syndrome1 trial

Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19 Infection

No longer available·MMesoblast International Sàrl··NCT04366830

Pediatric Patients1 trial

Prochymal Expanded Access Treatment for Pediatric Patients Who Have Failed Steroids for Acute GVHD

No longer available·MMesoblast, Ltd.··NCT00759018

2 more indications

Acute Graft Versus Host Disease1 trial

A Prospective Study of Remestemcel-L, Ex-vivo Cultured Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute Graft-Versus-Host Disease (aGVHD)

Completed·MMesoblast, Ltd.·Phase 3·NCT02336230·55 enrolled

Colitis1 trial

Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Crohn's Colitis

Unknown status·TThe Cleveland Clinic·Phase 1/2·NCT04548583·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Remestemcel-L. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Remestemcel-L compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Remestemcel-L. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Mesoblast, Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 3[1]
Company: MMesoblast, Ltd.

Remestemcel-L

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

COVID-192 trials

Ulcerative Colitis1 trial

Treatment1 trial

Acute Respiratory Distress Syndrome1 trial

Pediatric Patients1 trial

Acute Graft Versus Host Disease1 trial

Colitis1 trial

References

Drug Info

Quick Facts

Related News